Immorna Biotherapeutics Inc.

About Immorna Biotherapeutics Inc.

Immorna Biotherapeutics is a biotechnology company focused on innovation through RNA technology, aiming to transform somatic cells into drug factories and develop advanced mRNA-based therapies.

Products & Services

mRNA Platforms:Diverse pipeline utilizing multiple mRNA platforms, including conventional, self-replicating, and circular mRNA.

CDMO Services:Contract Development and Manufacturing Organization services for biotherapeutics.

Influenza/COVID-19 Combination mRNA Vaccine:Next-generation vaccine with enhanced immunogenicity for B influenza antigens.

JCXH-213 CAR Therapy:Breakthrough mRNA-based in vivo CAR therapy for clinical administration.

JCXH-211 IV Therapy:Therapy for advanced solid tumors, approved for Phase 1/2 study as monotherapy and in combination with checkpoint inhibitors.

mRNA RSV Vaccine:Vaccine under clinical development for Respiratory Syncytial Virus.

Specialties

RNA Technology mRNA Vaccines mRNA-based Therapies In Vivo CAR Therapy Solid Tumor Treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 3800000 MR: - FA: $3,800,000 FAN: 3800000	D: 2024-08-26 FD: 2024-08-26	1 investors

Grant Latest

2024-08-26

$3.8M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Z

Zihao Wang

CEO & Co-founder

Z

Zhijun Guo

CTO & Co-founder

Y

Yuanqing Liu

CSO, China

N

NgocDiep Le

President and Global CMO

J

Jeffrey Ulmer

Chief Scientific Advisor

K

Kexin Zhang

SVP, Head of Strategic Operations

View 8 more team members with Pro

Unlock Full Team Directory

Recent News